Recently, the USFDA has ordered all the Ranitidine manufacturers to withdraw their products from the market claiming that the drug poses a risk of carcinogenicity due to the presence of N-Nitrosodimethylamine (NMDA) . FDA has asked all the consumers on prescription or on an over-the-counter basis to stop taking the drug and look for another alternative to treat their condition. In 2019, some of the testing laboratories reported the presence of N-Nitrosodimethylamine (NDMA) , a probable human carcinogen in some Ranitidine products. Following this, the FDA conducted thorough laboratory tests that confirmed the presence of low levels of NDMA in the drug.
After investigation, the agency had reported that the impurity in some Ranitidine products increases over time and when stored at higher than room temperatures. This may expose consumers to the risk of cancer. Hence, the FDA issued a…
